Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT + serplulimab + XELOX + bevacizumab for MSS/pMMR locally advanced colorectal cancer
ChiCTR2600122492Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of serplulimab in colorectal cancer (CRC) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Complete response rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600122492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122492.